How Much Does Vyvanse Cost in Connecticut in 2026?

Vyvanse List Price vs. What Connecticut Patients Actually Pay

Takeda Pharmaceuticals lists Vyvanse at $390 per month for a 30-day supply of brand-name capsules. That number rarely reflects what a patient hands over at the pharmacy counter. The average cash-pay price across Connecticut retail pharmacies in 2026 runs approximately $35 per month when patients use a discount card or coupon program.

Why the gap? The FDA approved generic lisdexamfetamine dimesylate capsules in August 2023, and multiple manufacturers now produce them. Generic competition compressed retail pricing significantly. A patient filling a 30-day prescription for lisdexamfetamine 30 mg at a chain pharmacy like CVS or Walgreens in Hartford, New Haven, or Stamford can expect to see quotes ranging from $25 to $55, depending on the specific dose strength and the pharmacy's acquisition cost. Higher strengths (50 mg, 70 mg) trend slightly more expensive, but the difference is modest.

The Vyvanse prescribing label notes that lisdexamfetamine is a prodrug converted to dextroamphetamine after oral absorption, a pharmacokinetic design that provides consistent plasma levels across approximately 13 hours [1]. This once-daily dosing eliminates the need for multiple fills or split-dose prescriptions, which keeps monthly costs predictable.

Patients who still want brand-name Vyvanse and lack insurance coverage face the full $390 list price. For most Connecticut residents, the generic or a discount program makes that scenario avoidable.

Connecticut Medicaid Coverage for Vyvanse

Connecticut Medicaid (HUSKY Health) covers Vyvanse and generic lisdexamfetamine, but requires prior authorization (PA). The PA process typically involves documentation that the patient has a confirmed diagnosis of ADHD or binge eating disorder and that the prescriber has considered first-line agents.

Connecticut's preferred drug list (PDL) generally favors immediate-release amphetamine salts and methylphenidate formulations as first steps for ADHD. If a patient has tried and failed one of these, or has a clinical reason to start on a long-acting prodrug, the PA is usually approved within 24 to 72 hours.

A few practical details for Connecticut Medicaid enrollees:

• Prior authorization criteria: diagnosis of ADHD (DSM-5) or binge eating disorder (BED), age-appropriate use, and documentation of therapeutic rationale.
• Appeal timelines: if the initial PA is denied, Connecticut allows a 15-day appeal window. Expedited reviews are available for urgent clinical situations.
• Generic substitution: most Connecticut Medicaid plans will auto-substitute generic lisdexamfetamine unless the prescriber writes "brand medically necessary" and provides supporting documentation.

Wigal et al. demonstrated in a randomized controlled trial (N=314) that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV scores compared to placebo across all dose levels tested, supporting the clinical rationale that Medicaid PA reviewers evaluate [2]. That study's effect sizes give prescribers concrete data to cite on PA forms.

Commercial Insurance Options in Connecticut

Major commercial insurers operating in Connecticut, including Anthem Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, generally include lisdexamfetamine on their formularies. Coverage tiers and copay amounts vary.

Most plans place generic lisdexamfetamine on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), with copays ranging from $10 to $45 per month. Brand-name Vyvanse, when explicitly requested, often sits on Tier 3 or a specialty tier with copays from $50 to $150. Some plans require step therapy, meaning the patient must try and document inadequate response to a cheaper stimulant before lisdexamfetamine is approved.

The Connecticut Insurance Department requires all fully insured plans sold in the state to comply with mental health parity laws under both the federal Mental Health Parity and Addiction Equity Act and Connecticut General Statute §38a-514. This means ADHD medication coverage cannot impose more restrictive limits than those applied to medications for physical health conditions.

Patients with high-deductible health plans (HDHPs) may pay full price until meeting their deductible. In those cases, using a manufacturer coupon or pharmacy discount card alongside insurance can reduce the out-of-pocket burden during the deductible phase.

The Takeda Savings Card: How It Works in Connecticut

Takeda offers a Vyvanse Savings Card (also called the MyVyvanseSavings program) that can reduce copays for commercially insured patients. The card does not work with government insurance programs, including Medicaid, Medicare, TRICARE, or VA benefits.

Here is how the program functions:

• Eligible patients pay as little as $30 per 30-day fill for brand-name Vyvanse.
• Annual cap: the card covers up to a set dollar amount per year (historically around $3 to 600 in manufacturer subsidy per patient per year, though Takeda adjusts this periodically).
• Activation: patients can enroll online at Takeda's patient support site or receive a card from their prescriber's office.
• Pharmacy processing: the savings card is run as a secondary payer at the pharmacy point of sale. The pharmacist processes insurance first, then applies the savings card to reduce the remaining copay.

One thing to flag: now that generic lisdexamfetamine is widely available, the savings card is most useful for patients whose prescriber has specified brand Vyvanse specifically. Patients filling the generic may find that their insurance copay or a GoodRx-style discount card already brings the cost below what the Takeda card offers.

Connecticut pharmacies report that roughly 78% of new lisdexamfetamine prescriptions in 2026 are filled as generic, a shift from under 20% in early 2024 when generic supply was still ramping up.

Compounded Lisdexamfetamine in Connecticut

Compounded lisdexamfetamine is legal in Connecticut through licensed 503A compounding pharmacies. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows patient-specific compounding based on a valid prescription from a licensed prescriber [3].

A few points specific to Connecticut:

• State board oversight: the Connecticut Department of Consumer Protection, Drug Control Division, licenses and inspects compounding pharmacies operating in the state.
• When compounding applies: the most common clinical reason for compounding lisdexamfetamine is a patient who cannot swallow capsules and needs a liquid formulation, or a patient who requires a non-standard dose not commercially available.
• Cost: compounded lisdexamfetamine pricing varies by pharmacy but can run from $0 to $80 per month depending on the formulation, with some 503A pharmacies offering promotional pricing for new patients.
• Insurance coverage: most commercial insurers and Connecticut Medicaid do not cover compounded medications. Patients typically pay cash.

The FDA's guidance on 503A compounding clarifies that compounded drugs are not FDA-approved and lack the same safety and efficacy data as manufactured products. Patients considering this route should discuss it directly with their prescriber.

Compounding becomes especially relevant for pediatric ADHD patients. Children who struggle with capsule swallowing may benefit from a compounded oral solution. The American Academy of Pediatrics recommends medication management as a component of ADHD treatment for children aged 6 and older, and access to an appropriate dosage form affects adherence [4].

Telehealth Prescribing of Vyvanse in Connecticut

Connecticut permits telehealth prescribing of Schedule II controlled substances, including Vyvanse and generic lisdexamfetamine. This was codified during the COVID-19 public health emergency and subsequently extended through Connecticut state legislation.

The DEA's updated telemedicine regulations (finalized in 2025) allow practitioners to prescribe Schedule II stimulants via telehealth under specific conditions: the prescriber must hold a valid Connecticut medical license, conduct an initial audio-video evaluation (audio-only is not sufficient for Schedule II initial prescriptions in most circumstances), and maintain a DEA registration [5].

Practical implications for Connecticut patients:

• Initial visit: must be a real-time video visit. The prescriber needs to complete a clinical evaluation including psychiatric history, current symptoms, and a risk assessment for substance use.
• Refills: follow-up visits for dose adjustments and prescription renewals can occur via telehealth without geographic restrictions within Connecticut.
• Pharmacy: the electronic prescription is sent directly to a Connecticut-licensed pharmacy. Because lisdexamfetamine is Schedule II, paper prescriptions are also accepted but not required under the state's electronic prescribing mandate (Connecticut mandated EPCS for controlled substances starting in 2018).
• Multi-state considerations: if a patient sees a telehealth provider licensed in another state, that provider must also hold a Connecticut license or practice under an interstate compact that Connecticut recognizes.

Several national telehealth platforms (Done, Cerebral, Talkiatry, and others) operate in Connecticut and prescribe stimulant medications following these rules. Wait times for ADHD evaluations through telehealth in Connecticut averaged 5 to 14 days in early 2026, shorter than the 4-to-8-week wait common for in-person psychiatry appointments in the state.

Discount Programs and Assistance Beyond Insurance

Connecticut residents who are uninsured or underinsured have several options beyond the Takeda savings card:

GoodRx, RxSaver, and similar discount platforms: these aggregate negotiated cash prices from participating Connecticut pharmacies. Searching for generic lisdexamfetamine 30 mg on these platforms typically returns prices between $25 and $50 for a 30-day supply at major chain pharmacies in Bridgeport, Hartford, New Haven, and Stamford.

Takeda Patient Assistance Program (Takeda HELP at Hand): for uninsured patients with household income at or below 250% of the federal poverty level, Takeda offers brand-name Vyvanse at no cost. The application requires income documentation and a prescriber signature.

Connecticut Pharmaceutical Assistance Contract to the Elderly and Disabled (ConnPACE): this state program assists Connecticut residents aged 65+ or those receiving Social Security Disability with prescription costs. Lisdexamfetamine may be covered depending on the patient's specific plan and formulary.

340B pharmacies: federally qualified health centers (FQHCs) and other 340B-eligible entities in Connecticut can purchase lisdexamfetamine at a steep discount and pass savings to qualifying patients. The Community Health Center, Inc. (CHC), which operates multiple sites across Connecticut, participates in the 340B program.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has stated: "Cost should never be the reason a patient with ADHD stops taking a medication that is working. Between generics, patient assistance programs, and formulary alternatives, most patients can find an affordable path" [6].

How Lisdexamfetamine Compares to Other ADHD Medications on Cost

Connecticut patients weighing lisdexamfetamine against other stimulant options should consider both efficacy data and pricing. A rough comparison of average monthly cash-pay prices (with discount card) across Connecticut pharmacies in 2026:

• Generic lisdexamfetamine (Vyvanse equivalent): ~$35
• Generic mixed amphetamine salts XR (Adderall XR equivalent): ~$30 to $45
• Generic methylphenidate ER (Concerta equivalent): ~$25 to $40
• Brand-name Vyvanse: ~$390
• Brand-name Adderall XR: ~$350
• Brand-name Concerta: ~$370

Lisdexamfetamine's prodrug mechanism, which requires enzymatic cleavage in red blood cells to release active dextroamphetamine, provides a pharmacokinetic profile with lower peak-to-trough variability compared to mixed amphetamine salts XR. Wigal et al. documented that this translated to consistent symptom control from early morning through early evening in their 2017 study of 314 participants [2]. For patients who experience late-afternoon rebound with other long-acting stimulants, that pharmacokinetic advantage may justify any small cost premium.

The Endocrine Society and the American Academy of Child and Adolescent Psychiatry (AACAP) both recommend individualized medication selection based on patient response, tolerability, and practical factors including cost and adherence [7]. A medication that costs $10 less per month but requires a booster dose at 3 PM (creating adherence challenges for a middle-school student) may not actually be the cheaper option over time.

Connecticut-Specific Regulatory Notes

Connecticut classifies lisdexamfetamine as a Schedule II controlled substance, consistent with federal scheduling. State-specific prescribing rules include:

• Prescription limits: Connecticut allows up to a 30-day supply per prescription for Schedule II substances. Prescribers may issue up to three sequential 30-day prescriptions at a single visit, with future "do not fill before" dates.
• PDMP requirements: Connecticut's Prescription Drug Monitoring Program (CPMRS) requires prescribers to check the database before writing a Schedule II prescription and at minimum every 90 days for ongoing treatment. Pharmacists must report dispensing within 24 hours [8].
• ID requirements: Connecticut pharmacies require valid photo identification when dispensing Schedule II controlled substances.

These safeguards are standard for stimulant medications and do not create unusual barriers to access for patients with legitimate prescriptions.

The overall cost picture for Vyvanse in Connecticut is markedly better than it was two years ago. Generic entry compressed prices by roughly 90% from list, Medicaid covers it with PA, and multiple assistance programs exist for patients who fall through coverage gaps. A Connecticut patient starting lisdexamfetamine today should expect to pay between $0 and $50 per month in most scenarios.